核苷类似物只能诱导暂时的乙肝e抗原血清转化

tonychant

Background & Aims: Inconsistencies in results and guideline recommendations regarding the durability of nucleos(t)ide analogue-induced hepatitis B e antigen (HBeAg) seroconversion require clarification. We studied the long-term durability of nucleos(t)ide analogue-induced HBeAg seroconversion in patients with chronic hepatitis B virus (HBV) infection. Methods: We performed a single-center cohort study of 132 HBeAg-positive patients who had received nucleos(t)ide analogue therapy. Results: During a median treatment duration of 26 months (range, 16-43 mo), HBeAg seroconversion occurred in 46 of 132 subjects (35%). Forty-two subjects (91%) had follow-up evaluation after HBeAg seroconversion. During a median follow-up period of 59 months (range, 28-103 mo) after HBeAg seroconversion, 13 of 42 patients (31%) showed a durable remission (defined as HBeAg negative and HBV-DNA level <10,000 copies/mL). Overall, 33 of 42 subjects (79%) continued therapy after HBeAg seroconversion, of these, 22 (67%) showed serologic and/or virologic recurrence. Nine of 42 subjects (21%) discontinued therapy after HBeAg seroconversion and at least 6 months of consolidation therapy. Only 2 patients showed a durable response in the absence of therapy. Disease recurrence in patients who continued therapy after HBeAg seroconversion was preceded by the development of resistance (80% of these patients), resistance only occurred in subjects given lamivudine monotherapy. In contrast, recurrence after treatment discontinuation or noncompliance was observed in all patients given nucleos(t)ide analogues. Conclusions: Induction of HBeAg seroconversion by nucleos(t)ide analogues is temporary in most patients with chronic HBV infection. Long-term continuation of nucleos(t)ide analogue treatment, irrespective of the occurrence of HBeAg seroconversion, appears to be necessary. © 2010 AGA Institute.

anny8527

懂点英文了是不？俺看不懂  能翻译下啊  呵呵

lin12345

目的：核苷（酸）IDE类似物诱导B型肝炎e抗原e抗原（HBeAg）血清转换的持久性的结果和有关指引建议不一致需要澄清。我们研究慢性乙型肝炎病毒（HBV）感染患者的核苷（酸）IDE类似物诱导的HBeAg血清转换的长期耐久性。方法：我们收到核苷（酸）IDE类似物治疗的HBeAg阳性者132患者进行了单中心队列研究。结果：在一个26个月的平均治疗时间（范围16-43月），46 132个科目（35％）发生HBeAg血清转换。 44个科目（91％），HBeAg血清转换后的后续评价。在一个中位随访期59个月后HBeAg血清转换，（范围28-103 MO）42例（31％）13显示持久缓解（定义为HBeAg阴性，HBV - DNA水平<10,000拷贝/ mL） 。总体而言，42个学科（79％）33个HBeAg血清转换后继续治疗这些，22（67％），血清和/或病毒学复发。 42学科9个（21％），HBeAg血清转换后停止治疗和巩固治疗至少6个月。仅2例显示了一个在没有治疗的情况下持久的反应。在继续治疗后HBeAg血清学转换是发展的阻力（80％），这些患者之前的患者的疾病复发，抗只发生在拉米夫定单一治疗的受试者。相比之下，停药后或违规的复发，观察所有患者给予核苷（酸）IDE类似物。结论：核苷（酸）IDE类似物对HBeAg血清转换的电磁炉是临时在慢性HBV感染的最患者。核苷（酸）IDE模拟治疗的长期延续，不论HBeAg血清转换的发生，似乎是必要的。 © 2010 AGA公司研究所。